{"id":"W4381734434","doi":"10.2337/db23-53-or","title":"53-OR: Efficacy and Safety of Coadministered s.c. Semaglutide and s.c. Cagrilintide in Type 2 Diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Discontinuation; Semaglutide; Clinical endpoint; Type 2 diabetes; Weight loss; Internal medicine; Glycemic; Randomized controlled trial; Hypoglycemia; Exenatide; Adverse effect; Metformin; Diabetes mellitus; Insulin; Endocrinology; Obesity","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007067678,0.0005717825,0.001650168,0.0002678373,0.0002042995,0.0004728226,0.0004559224,0.000827054,0.006824372],"category_scores_gemma":[0.0006145539,0.0002215207,0.001146183,0.0002416847,0.0003895493,0.000570747,0.0002555277,0.001413475,0.001059827],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003542281,"about_ca_system_score_gemma":0.0004106614,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005878353,"about_ca_topic_score_gemma":0.001533845,"domain_scores_codex":[0.999595,0.0001877174,0.00003201528,0.00006652022,0.00004379719,0.00007482893],"domain_scores_gemma":[0.999731,0.00005597824,0.00007562819,0.00002809348,0.00001596381,0.00009331553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7695135,0.0199302,0.004023109,0.001160826,0.001644839,0.000273631,0.00008103673,0.0007764231,0.04270016,0.0002011141,0.002070578,0.1576245],"study_design_scores_gemma":[0.4600862,0.4899882,0.02877979,0.0002065829,0.001938139,0.0006034893,0.0001095761,0.002249193,0.01246142,0.0001616393,0.003359693,0.00005599844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940405,0.00233739,0.0002853529,0.0002104775,0.0001077316,0.0003084038,0.0003965569,0.0001320532,0.002181437],"genre_scores_gemma":[0.9946653,0.001270201,0.0005820657,0.0003452299,0.0001251262,0.0003038414,0.0006071884,0.00001856365,0.002082479],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006824372,"threshold_uncertainty_score":0.02282983,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0146144983443155,"score_gpt":0.2640294423013727,"score_spread":0.2494149439570572,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}